Literature DB >> 7490826

Decrease in mortality from benign prostatic hyperplasia: a major unheralded health triumph.

P Boyle1, P Maisonneuve, A Steg.   

Abstract

PURPOSE: A systematic examination of all available mortality data from benign prostatic hyperplasia (BPH) between 1950 and 1990 was done to estimate the changing international mortality pattern of this condition.
MATERIALS AND METHODS: Mortality data in which BPH was the underlying cause of death were abstracted from the World Health Organization mortality data base. These data were available from a variety of international countries (in many since 1950).
RESULTS: Mortality rates have decreased with considerable magnitude in developed western countries between the early 1950s and late 1980s. This fact could reasonably be attributed to the improved management of the most severe complications of BPH and to improvements in surgery and anesthesia, which have made surgical interventions of the prostate possible in a greater proportion of men, and safer in the immediate and subsequent postoperative period.
CONCLUSIONS: The decreases noted in western countries, such as the United Kingdom (where 8,700 fewer men die each year presently than would be expected if the BPH mortality rates from the early 1950s still applied), United States (13,681 fewer deaths) and France (2,884 fewer deaths), indicate a considerable but unheralded achievement for modern medicine. Unfortunately, these decreases have not been observed to the same extent in central and eastern Europe and South America, where the residual high mortality rates could be lowered by education, and the widespread availability of modern surgical and anesthetic equipment.

Entities:  

Mesh:

Year:  1996        PMID: 7490826

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  8 in total

Review 1.  Drug treatments for lower urinary tract symptoms secondary to bladder outflow obstruction: focus on quality of life.

Authors:  Donald MacDonald; Thomas A McNicholas
Journal:  Drugs       Date:  2003       Impact factor: 9.546

2.  Global implementation of advanced urological care: Policy implementation research.

Authors:  Lynn Stothers; Andrew Macnab
Journal:  Can Urol Assoc J       Date:  2017-06       Impact factor: 1.862

3.  Prevalence estimates for lower urinary tract symptom severity among men in Uganda and sub-Saharan Africa based on regional prevalence data.

Authors:  Francis Bajunirwe; Lynn Stothers; Jonathan Berkowitz; Andrew J Macnab
Journal:  Can Urol Assoc J       Date:  2018-06-08       Impact factor: 1.862

Review 4.  Treatment of benign prostatic hyperplasia. A pharmacoeconomic perspective.

Authors:  L M Eri; K J Tveter
Journal:  Drugs Aging       Date:  1997-02       Impact factor: 3.923

Review 5.  Early treatment of benign prostatic hyperplasia: implications for reducing the risk of permanent bladder damage.

Authors:  Andrea Tubaro; Simon Carter; Alberto Trucchi; Giorgio Punzo; Stefano Petta; Lucio Miano
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

6.  Associations between the severity of obstructive lower urinary tract symptoms and care-seeking behavior in rural Africa: A cross-sectional survey from Uganda.

Authors:  Lynn Stothers; Andrew J Macnab; Francis Bajunirwe; Sharif Mutabazi; Jonathan Berkowitz
Journal:  PLoS One       Date:  2017-03-16       Impact factor: 3.240

7.  The role of international partnerships in improving urethral reconstruction in low- and middle-income countries.

Authors:  Maahum Haider; Mohamed Jalloh; Jiaqi Yin; Amadou Diallo; Nancy Puttkammer; Serigne Gueye; Lamine Niang; Hunter Wessells; Kurt McCammon
Journal:  World J Urol       Date:  2019-06-08       Impact factor: 4.226

8.  An Analytical Study of Prostate-Specific Antigen Dynamics.

Authors:  Ernesto P Esteban; Giovanni Deliz; Jaileen Rivera-Rodriguez; Stephanie M Laureano
Journal:  Comput Math Methods Med       Date:  2016-11-13       Impact factor: 2.238

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.